Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Spencer Trask & Co. launches Signal12 for Dry Eye Disease treatment, led by former Aerie executives, advancing Pro-ocular through trials

Spencer Trask & Co. the advanced technology development firm, announced today the launch of Signal12 Inc. (Signal12), a clinical-stage dry eye company. Signal12 is revolutionizing treatments for Dry Eye Disease (DED) and eliminating the hassle of...

Persist AI and Nivagen partner to develop AI-driven manufacturing for long-acting injectables

Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, using Persist's AI-based formulation technology and Nivagen's manufacturing capabilities. The...

Biosyngen's BRG01 gets FDA approval for Phase II clinical trial.

Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI...

Stay Protected

As health needs evolve throughout life, it can be easy to forget how crucial vaccinations can be for protecting against preventable diseases. Many associate vaccines with childhood, remembering the series of shots received during early school...

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior...

Axion BioSystems extends its agreement with Corning®, granting exclusive rights to distribute its award-winning cell counting device.

Axion BioSystems announced an agreement with Corning Incorporated that continues Corning’s exclusive worldwide distribution rights for the Corning® Cell Counter. The simple yet powerful device, developed by Axion BioSystems and distributed by...

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, today announced the first cohort of participants has been dosed in a Phase 1 trial...

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Canada to the commercialization of clobetasol propionate ophthalmic suspension,...

Sensitech acquires Berlinger & Co. to expand life sciences cold chain solutions

Carrier Global Corporation, on behalf of its Sensitech business, a world leader in supply chain visibility, has completed its acquisition of the Monitoring Solutions business of Berlinger & Co. AG, a Swiss family-owned company that specializes in...

Jade Biosciences launches with $80 million to develop transformative autoimmune disease therapies

Jade Biosciences, Inc. a biotechnology company dedicated to developing best-in-class therapies for patients living with autoimmune diseases, announced the closing of an $80 million financing. The financing was led by Fairmount and Venrock...

Eximia Research Network expands into Virginia by integrating Tidewater Clinical Research

Eximia Research announces the integration of Tidewater Clinical Research into its national network of clinical trial sites. This strategic development unites Tidewater's longstanding expertise in Women's Health and Ophthalmology with Eximia's...

Inoviv launches MasterKey™, a customizable platform for multiplexed protein assays

Inoviv announces the launch of MasterKey™, which enables researchers to select specific proteins from a comprehensive, pre-characterized catalog of thousands of proteins. This database is built from years of extensive research, utilizing technical...

Clarivate introduces the new OFF-X™ platform for preclinical and clinical safety intelligence

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the launch of the new OFF-X™ platform. The enhanced solution offers a seamless user experience and unique translational insights. It delivers crucial...

Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe

Galderma announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA – previously referred to as QM1114). RelfydessTM is indicated for the temporary improvement...

Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients

Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the...

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

NewAmsterdam Pharma Company N.V a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”). For whom...

AIM ImmunoTech announces the release of the next CEO Corner segment

AIM ImmunoTech Inc. announced the next CEO Corner segment has been published on the Company’s website. In the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial...

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio's Phase...

Astellas gets positive CHMP opinion for PADCEV™ and KEYTRUDA® combo in advanced bladder cancer.

Astellas Pharma Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV™ (enfortumab vedotin, an antibody-drug conjugate...

Teva and Sanofi Announce Accelerated Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Sanofi announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal...